KPTI vs. RPTX, CTXR, VTGN, ANVS, EBS, AMLX, GLYC, RLMD, INCR, and PDSB
Should you be buying Karyopharm Therapeutics stock or one of its competitors? The main competitors of Karyopharm Therapeutics include Repare Therapeutics (RPTX), Citius Pharmaceuticals (CTXR), Vistagen Therapeutics (VTGN), Annovis Bio (ANVS), Emergent BioSolutions (EBS), Amylyx Pharmaceuticals (AMLX), GlycoMimetics (GLYC), Relmada Therapeutics (RLMD), InterCure (INCR), and PDS Biotechnology (PDSB). These companies are all part of the "pharmaceutical preparations" industry.
Karyopharm Therapeutics (NASDAQ:KPTI) and Repare Therapeutics (NASDAQ:RPTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, community ranking, dividends and institutional ownership.
Repare Therapeutics has lower revenue, but higher earnings than Karyopharm Therapeutics. Repare Therapeutics is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.
Karyopharm Therapeutics has a beta of 0.03, meaning that its stock price is 97% less volatile than the S&P 500. Comparatively, Repare Therapeutics has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500.
Karyopharm Therapeutics presently has a consensus price target of $5.67, indicating a potential upside of 434.59%. Repare Therapeutics has a consensus price target of $17.33, indicating a potential upside of 441.67%. Given Repare Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Repare Therapeutics is more favorable than Karyopharm Therapeutics.
Karyopharm Therapeutics received 491 more outperform votes than Repare Therapeutics when rated by MarketBeat users. Likewise, 72.02% of users gave Karyopharm Therapeutics an outperform vote while only 60.71% of users gave Repare Therapeutics an outperform vote.
66.4% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 85.1% of Repare Therapeutics shares are held by institutional investors. 3.3% of Karyopharm Therapeutics shares are held by company insiders. Comparatively, 28.5% of Repare Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, Repare Therapeutics had 2 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 4 mentions for Repare Therapeutics and 2 mentions for Karyopharm Therapeutics. Repare Therapeutics' average media sentiment score of 0.62 beat Karyopharm Therapeutics' score of -0.50 indicating that Repare Therapeutics is being referred to more favorably in the news media.
Karyopharm Therapeutics has a net margin of -97.99% compared to Repare Therapeutics' net margin of -183.43%. Karyopharm Therapeutics' return on equity of 0.00% beat Repare Therapeutics' return on equity.
Summary
Repare Therapeutics beats Karyopharm Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Karyopharm Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KPTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Karyopharm Therapeutics Competitors List
Related Companies and Tools
